1.
Product Overview
2.
Research Methodology
3.
Impact of COVID-19 on Japan Generic Drugs Market
4.
Voice of Customer
5.
Executive Summary
6. Japan Generic Drugs
Market Outlook
6.1.
Market Size & Forecast
6.1.1.
By Value
6.2.
Market Share & Forecast
6.2.1.
By Type (Small Molecule Generics v/s Biosimilars)
6.2.2.
By Mode of Drug Delivery (Oral, Topical, Parenteral,
Others)
6.2.3.
By Form (Tablet, Capsule, Injection, Others)
6.2.4.
By Source (In House v/s Contract Manufacturing
Organizations)
6.2.5.
By Distribution Channel (Hospital Pharmacies, Retail
Pharmacies, Online Pharmacies, Others)
6.2.6.
By Application (Cardiovascular Diseases, Diabetes,
Neurology, Oncology, Anti-Inflammatory Diseases, Others)
6.2.7.
By Company (FY2021)
6.2.8. By
Region
6.3.
Product Market Map
7. Japan Small Molecule
Generic Drugs Market Outlook
7.1.
Market Size & Forecast
7.1.1.
By Value
7.2.
Market Share & Forecast
7.2.1.
By Mode of Drug Delivery
7.2.2.
By Form
7.2.3.
By Source
7.2.4.
By Distribution Channel
7.2.5.
By Application
8. Japan Biosimilar
Generic Drugs Market Outlook
8.1.
Market Size & Forecast
8.1.1.
By Value
8.2.
Market Share & Forecast
8.2.1.
By Mode of Drug Delivery
8.2.2.
By Form
8.2.3.
By Source
8.2.4.
By Distribution Channel
8.2.5.
By Application
9.
Market Dynamics
9.1.
Drivers
9.2.
Challenges
10.
Market Trends & Developments
11.
Policy & Regulatory Landscape
12.
Japan Economic Profile
13.
Competitive Landscape
13.1.
Competition Outlook
13.2.
Company Profiles
13.2.1.
Nichi-Iko
Pharmaceutical Co., Ltd.
13.2.2.
Sawai Pharmaceutical
Co., Ltd.
13.2.3.
Towa Pharmaceutical
Co., Ltd.
13.2.4.
Nipro Corporation
13.2.5.
Daiichi Sankyo Co.,
Ltd.
13.2.6.
Meiji Holdings Co.,
Ltd.
13.2.7.
Nihon Chouzai Co.,
Ltd.
13.2.8.
Kyorin
Pharmaceutical Co., Ltd.
13.2.9.
Aska Pharmaceutical
Co., Ltd.
13.2.10.
Takeda Pharmaceutical Company Limited
13.2.11.
Astellas Pharma Inc
13.2.12.
Otsuka Pharmaceutical Co., Ltd.
14. Strategic Recommendations
15. About Us &
Disclaimer